In a report published Thursday, Jefferies analyst Raj Denhoy reiterated a Hold rating on St. Jude Medical STJ, and raised the price target from $39.00 to $42.00.
In the report, Denhoy noted, “1Q sales were a bit light despite modestly better ICDs as all other businesses underperformed, most notably international pacemakers. While the top line is expected to accelerate over the balance of the year versus just -3% cc in 1Q as new products are launched, weak core markets will continue to weigh on growth. Absent negative Durata news, downside appears limited as tepid growth is balanced with earnings support, keeping us at Hold.”
St. Jude Medical closed on Wednesday at $42.14.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in